Skip to main content

Language: English / Gàidhlig

Loading…

Seòmar agus comataidhean

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

  • Written questions must be answered within 10 working days (20 working days during recess)
  • Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search.  There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Criathragan Hide all filters

Dates of parliamentary sessions
  1. Session 1: 12 May 1999 to 31 March 2003
  2. Session 2: 7 May 2003 to 2 April 2007
  3. Session 3: 9 May 2007 to 22 March 2011
  4. Session 4: 11 May 2011 to 23 March 2016
  5. Session 5: 12 May 2016 to 5 May 2021
  6. Current session: 12 May 2021 to 25 November 2024
Answer status
Question type

Displaying 448 questions Show Answers

|

Question reference: S6W-29685

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ozanimod (Zeposia) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29682

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe glatiramer acetate (Copaxone) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29689

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe siponimod (Mayzent) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29628

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Siobhian Brown on 18 September 2024

To ask the Scottish Government what multi-year funding it can provide to advice services on the Western Isles to ensure that islanders are able to continue to access free legal advice.

Question reference: S6W-29683

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe natalizumab (Tysabri) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29676

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe alemtuzumab (Lemtrada) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29687

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ponesimod (Ponvory) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29677

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe Avonex (interferon beta-1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29690

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe teriflunomide (Aubagio) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29686

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe Plegridy (peginterferon beta 1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.